One Quality Standard

One Quality Standard

Our mission is to provide 7 billion people with access to high-quality medicine. But access is about more than stocking chemist's shelves.

It’s all about driving and championing policy. Policies that improve access. Policies designed to change restrictive laws that limit access. And polices that promote one global standard of quality for all medicines.

Why so passionate about policy?
Because we believe in breaking down the barriers between safe, effective and affordable medicines and the people all over the world who need them.

Policies We Support

Promoting One Quality Standard
U.S. legislation, including the Food and Drug Administration Safety and Innovation Act and the Generic Drug User Fee Amendments, expand the global reach of the Food and Drug Administration and ensure regular inspection of, and high quality standards for, all manufacturing facilities that supply the U.S. pharmaceutical market.
Increasing Generic Utilisation
In the U.S. generic utilisation saved more than $1.2 trillion from 2003 to 2012. In countries where utilisation is low, we’re educating governments about the role of generics in providing affordable healthcare and access to medicine.
Driving Biogeneric Access
Biogenerics are generic equivalents of biologics—expensive medicines for diseases like multiple sclerosis, rheumatoid arthritis, diabetes and cancer. We promote effective biogeneric approval pathways that drive interchangeability, maximise patient access to more affordable, high-quality biologics and reduce healthcare spending.
Raising Anaphylaxis Awareness
Food allergy is the most common cause of anaphylaxis, a life-threatening allergic reaction that demands immediate treatment with adrenaline. Food allergies affect approximately one in 13 U.S. children. We advocate for policy that expands access to adrenaline auto-injectors to entities such as schools.
Stemming HIV/AIDS
Approximately 35 million people in the developing world are infected with HIV, the virus that causes AIDS. Twenty-eight million need treatment. Less than a quarter of them receive it. We advocate for funding to focus on proven methods of treatment and prevention.